← Leaderboards
Ryan Scott Hippman
University Of Illinois At Chicago
$134,257
Attributed
$134,257
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $45.6K · FY2021–23$50K$37.5K$25K$12.5K$0
'21
'22
'23
Funding mix
By agency
NIH$134,257 · 1
By mechanism
F31$134,257 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Arshad Rahman$8,589,196
- John M Pezzuto$2,202,476
- Deepak Shukla$19,733,938
- Elizabeth Kaweesa$241,944
- Jagadeesh Ramasamy$455,195
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectAqueousAnalogAutophagosomeBiologicalBiological MarkersBioluminescenceAutophagocytosisCancer CellCancer Cell LineCancer PatientCancer TherapyCatabolic ProcessCell DeathCell LineCell Membrane PermeabilityCell PhysiologyCellsCell SurvivalChloroquineCommunicationComplexCounterscreenCoupling
Grant awards (3)
Development of an autophagy-specific inhibitor for evaluation as a therapeutic strategy in cancer.$45,619
F31 · FY2023 · CA · contact PI
Development of an autophagy-specific inhibitor for evaluation as a therapeutic strategy in cancer.$44,677
F31 · FY2022 · CA · contact PI
Development of an autophagy-specific inhibitor for evaluation as a therapeutic strategy in cancer.$43,961
F31 · FY2021 · CA · contact PI